![Stefania Landolfi on X: "Residual Cancer Burden evaluation in post-NAST #Breastpath #USCAP2018 #insitupathologists https://t.co/4GSxTI47S5" / X Stefania Landolfi on X: "Residual Cancer Burden evaluation in post-NAST #Breastpath #USCAP2018 #insitupathologists https://t.co/4GSxTI47S5" / X](https://pbs.twimg.com/media/DYlT9WBVoAA6vFS.jpg)
Stefania Landolfi on X: "Residual Cancer Burden evaluation in post-NAST #Breastpath #USCAP2018 #insitupathologists https://t.co/4GSxTI47S5" / X
![Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology](https://www.thelancet.com/cms/attachment/34b2410d-db54-46e1-ac1d-1d1894292938/gr1_lrg.gif)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
![Cancers | Free Full-Text | Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center Cancers | Free Full-Text | Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center](https://www.mdpi.com/cancers/cancers-14-01330/article_deploy/html/images/cancers-14-01330-g001-550.jpg)
Cancers | Free Full-Text | Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center
![Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore | British Journal of Cancer Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-020-01251-3/MediaObjects/41416_2020_1251_Fig1_HTML.png)
Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore | British Journal of Cancer
![PDF) Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy PDF) Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy](https://i1.rgstatic.net/publication/6054236_Measurement_of_Residual_Breast_Cancer_Burden_to_Predict_Survival_After_Neoadjuvant_Chemotherapy/links/0046353c1ad0bc6182000000/largepreview.png)
PDF) Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
![Cancers | Free Full-Text | Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity Cancers | Free Full-Text | Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity](https://www.mdpi.com/cancers/cancers-13-02492/article_deploy/html/images/cancers-13-02492-g001-550.jpg)
Cancers | Free Full-Text | Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
![Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment | Scientific Reports Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-50568-4/MediaObjects/41598_2019_50568_Fig1_HTML.png)
Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment | Scientific Reports
![Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/780f76a3-3de6-4daa-a475-37398a9d5e90/tbj13864-fig-0003-m.jpg)
Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library
![Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - 2023 - Thoracic Cancer - Wiley Online Library Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - 2023 - Thoracic Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b93ba2fb-ed63-4854-8cb2-511ef0a8ab71/tca14826-toc-0001-m.jpg?trick=1701686030800)
Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - 2023 - Thoracic Cancer - Wiley Online Library
![Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer - Wang - Gland Surgery Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer - Wang - Gland Surgery](https://cdn.amegroups.cn/journals/amepc/files/journals/11/articles/84318/public/84318-PB8-7986-R1.jpg/w300)
Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer - Wang - Gland Surgery
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy | PLOS ONE
![Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - 2023 - Thoracic Cancer - Wiley Online Library Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - 2023 - Thoracic Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5b78c760-89fe-4e8c-b4ff-aa91643515ef/tca.v14.11.cover.jpg)
Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - 2023 - Thoracic Cancer - Wiley Online Library
![Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology](https://www.thelancet.com/cms/attachment/aebe7284-f489-4fa5-a13d-db5ed5bcba73/gr2_lrg.jpg)